| College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer ME Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ... J Clin Oncol 28 (16), 2784-2795, 2010 | 5831* | 2010 |
| College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer AC Wolff, ME Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ... J clin oncol 25 (1), 118-145, 2007 | 5827 | 2007 |
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice … AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ... Archives of Pathology and Laboratory Medicine 138 (2), 241-256, 2014 | 5323 | 2014 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4301 | 2013 |
| A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer U Veronesi, G Paganelli, G Viale, A Luini, S Zurrida, V Galimberti, M Intra, ... New England Journal of Medicine 349 (6), 546-553, 2003 | 2864 | 2003 |
| Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes U Veronesi, G Paganelli, V Galimberti, G Viale, S Zurrida, M Bedoni, ... The Lancet 349 (9069), 1864-1867, 1997 | 2675 | 1997 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2647 | 2015 |
| Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update AC Wolff, MEH Hammond, KH Allison, BE Harvey, PB Mangu, ... Archives of pathology & laboratory medicine 142 (11), 1364-1382, 2018 | 2476 | 2018 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2225 | 2015 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2194 | 2012 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National cancer Institute 103 (22), 1656-1664, 2011 | 2019 | 2011 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2014 | 1859* | 2014 |
| 70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016 | 1852 | 2016 |
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition … S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ... J Clin Oncol 31 (7), 860-867, 2013 | 1747 | 2013 |
| Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ... Journal of the National Cancer Institute 98 (17), 1183-1192, 2006 | 1507 | 2006 |
| Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer G Von Minckwitz, M Procter, E De Azambuja, D Zardavas, M Benyunes, ... New England Journal of Medicine 377 (2), 122-131, 2017 | 1450 | 2017 |
| Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ... The lancet oncology 14 (4), 297-305, 2013 | 1280 | 2013 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1237 | 2017 |
| Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content S Pece, D Tosoni, S Confalonieri, G Mazzarol, M Vecchi, S Ronzoni, ... Cell 140 (1), 62-73, 2010 | 1118 | 2010 |
| Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ... Clinical cancer research 13 (11), 3207-3214, 2007 | 1088 | 2007 |
